Education
About Us
Working with TipRanks
Follow Us
Madrigal (MDGL)
:MDGL
MDGL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$189.00 - $377.46
Previous CloseN/A
Volume47.78K
Average Volume (3M)373.16K
Market Cap
$7.22B
Enterprise Value$5.96B
Total Cash (Recent Filing)$57.92M
Total Debt (Recent Filing)$1.71M
Price to Earnings (P/E)―
Beta1.00
Next Earnings
May 13, 2025EPS Estimate
-3.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-22.11
Shares Outstanding22,080,246
10 Day Avg. Volume248,051
30 Day Avg. Volume373,164
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)41.87
Price to Cash Flow (P/CF)-18.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.82
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit34.24
Enterprise Value/Ebitda-13.23
Forecast
1Y Price Target
$413.87Price Target Upside26.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
---
Madrigal Pharmaceuticals News
PremiumCompany Announcements
Madrigal Pharmaceuticals Expands Board with New Appointment
PremiumCompany Announcements
Madrigal’s Earnings Call Highlights Strong Growth
---
Bulls Say, Bears Say
Bulls Say
Commercial StrategyMDGL's marketing strategy is effectively targeting top prescribers, resulting in a significant number of prescriptions being written by key clinicians.
Financial PerformanceRezdiffra revenues beat sellside consensus and buyside expectations, showing strong performance for the drug.
Product LaunchRezdiffra's launch is gaining momentum, with strong patient demand and favorable physician prescribing trends.
Bears Say
Market CompetitionRezdiffra shows promising therapeutic benefits in NASH patients, which strengthens its market position amidst emerging competition.
Regulatory RiskMDGL confirmed that an EMA decision is expected with plans to commence a country-by-country launch beginning with Germany pending EMA approval.
---
Ownership Overview
19.56% Insiders
27.43% Mutual Funds
0.07% Other Institutional Investors
38.03% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MDGL FAQ
What was Madrigal’s price range in the past 12 months?
Madrigal lowest stock price was $189.00 and its highest was $377.46 in the past 12 months.
What is Madrigal’s market cap?
Madrigal’s market cap is $7.22B.
When is Madrigal’s upcoming earnings report date?
Madrigal’s upcoming earnings report date is May 13, 2025 which is in 38 days.
How were Madrigal’s earnings last quarter?
Madrigal released its earnings results on Feb 26, 2025. The company reported -$2.71 earnings per share for the quarter, beating the consensus estimate of -$3.92 by $1.21.
Is Madrigal overvalued?
According to Wall Street analysts Madrigal’s price is currently Undervalued.
Does Madrigal pay dividends?
Madrigal does not currently pay dividends.
What is Madrigal’s EPS estimate?
Madrigal’s EPS estimate is -3.74.
How many shares outstanding does Madrigal have?
Madrigal has 22,080,246 shares outstanding.
What happened to Madrigal’s price movement after its last earnings report?
Madrigal reported an EPS of -$2.71 in its last earnings report, beating expectations of -$3.92. Following the earnings report the stock price went up 14.989%.
Which hedge fund is a major shareholder of Madrigal?
Currently, no hedge funds are holding shares in MDGL
---
Madrigal Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$413.87 (26.53% Upside)
$413.87 (26.53% Upside)
Blogger Sentiment
Bullish
MDGL Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 160.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $24.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.5%
Last 30 Days ▲ 9.8%
Last 30 Days ▲ 9.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
33.38%
12-Months-Change
Fundamentals
Return on Equity
-80.35%
Trailing 12-Months
Asset Growth
62.71%
Trailing 12-Months
Company Description
Madrigal
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
---
MDGL Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Madrigal Pharmaceuticals demonstrated strong performance with the successful launch of Rezdiffra, significant prescriber engagement, and promising clinical data. Despite rising expenses and market challenges, the company's financial health and strategic positioning remain robust.Read More>---
MDGL Stock 12 Month Forecast
Average Price Target
$413.87
▲(26.53% Upside)
Technical Analysis
Altimmune
―
Galectin Therapeutics
―
Galmed Pharmaceuticals
―
Viking Therapeutics
―
Akero Therapeutics
―
Best Analysts Covering MDGL
1 Year
1 Year Success Rate
11/14 ratings generated profit
1 Year Average Return
+86.34%
reiterated a buy rating last month
Copying Ed Arce's trades and holding each position for 1 Year would result in 78.57% of your transactions generating a profit, with an average return of +86.34% per trade.
---